Janssen Pharmaceutica Nv

Johnson & Johnson Pharmaceuticals Research & Development, L.l.c.

Sharmila Patel

Mark R Player

Hui Huang

Wing S Cheung

Tianbao Lu

William H Parsons

Guozhang Xu

Daniel J Parks

Yu-Kai Lee

Jian Liu

Carl R Illig

Scott L Dax

Mark Andrew Youngman

Sanath K Meegalla

Kevin Douglas Kreutter

Jinsheng Chen

Gilles C Bignan

Micheal D Gaul

Raymond Joseph Patch

Kenneth Jerome Wilson

Kenneth M Wells

Bao-Ping Zhao

Venkatraman Mohan

Michele C Jetter

Lily Lee

Raul R Calvo

Wenxi Pan

Xun Li

Michael Richard Brandt

Derek A Beauchamp

Mark Fitzgerald

Raul L Calvo

Michael Brandt

Disclosed are compounds, compositions and methods for treating Type II diabetes and other disorders affected by activity of the enzyme PDE10a. Such compounds are represented by Formula (I) below, wherein R, R, L and Q are defined herein. 

PDE10a inhibitors for the treatment of type II diabetes

The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

Substituted thiazolidinedione indazoles, indoles and benzotriazoles as estrogen-related receptor-&#x3b1; modulators

The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.

Benzimidazole modulators of VR1

Benzimidazole TRPV1 inhibitors

Phenyl acetamide compounds are described, including compounds of Formula I: or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R-R, R, B, Y and W are set forth in the specification. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as thrombin and factor Xa. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

Substituted phenyl acetamides and their use as protease inhibitors

Growing community of inventors

Jamison, PA, United States of America

Sharmila Patel